Test Price
2,800 AED✅ Home Collection Available
SCN9A Gene Primary Erythromelalgia Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
Clinical Trust & Premium Service
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity achieved via ISO 9001:2015 certified laboratory and validated NGS bioinformatics pipeline.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection – Available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary Telephonic Post-Test Clinical Guidance by DHA-licensed genetic counsellors to explain variant interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 – we handle the paperwork before your draw.
Test Overview & Methodology
The SCN9A Gene Primary Erythromelalgia NGS Test sequences the entire coding region of the SCN9A gene to detect pathogenic mutations causing inherited erythromelalgia – a severe neuropathic pain disorder. This next-generation sequencing assay provides comprehensive genetic insights for accurate diagnosis, personalised pain management, and familial risk assessment.
| Feature | Our SCN9A NGS Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Technology | Next-Generation Sequencing (Illumina® platform) | Targeted Sanger Sequencing |
| Gene Coverage | Full coding exons + splice sites (±10 bp) | Single exon or selected mutation hotspots |
| Turnaround Time | 3 – 4 weeks | 6 – 8 weeks (multi-step confirmation required) |
| Clinical Utility | Comprehensive variant detection (SNVs, indels); ready for family screening | Limited to known familial mutation; low sensitivity for novel variants |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “Comprehensive sequencing of SCN9A is essential for differentiating inherited erythromelalgia from other neuropathic pain syndromes. Variant interpretation must be correlated with clinical phenotype and family history. This test enables precision pain management and informs genetic counseling for at-risk relatives.”
Medication Advisory
Do not discontinue prescribed pain medication, anticonvulsants, or antidepressants without consulting your treating physician. Abrupt cessation can provoke serious withdrawal symptoms and worsen erythromelalgia flares.
Exclusion Criteria & Emergency Red Flags
- Genetic testing is not performed during acute psychotic episodes or without prior genetic counselling.
- Minors require explicit legal guardian consent in compliance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- If you experience sudden intense pain with limb discoloration, coolness, or swelling, seek emergency care immediately — these may indicate a vascular emergency mimicking erythromelalgia.
Patient FAQ & Clinical Guidance
1. What is the SCN9A Gene Primary Erythromelalgia NGS Test?
This advanced genetic test sequences the entire SCN9A gene to identify pathogenic variants causing severe inherited burning pain and redness in extremities, confirming diagnosis and guiding targeted therapy.
2. How is the sample collected and processed?
A small blood sample or extracted DNA is collected via VIP Mobile Phlebotomy at your home by a certified phlebotomist, then analyzed using high-depth Next-Generation Sequencing with rigorous bioinformatics pipelines.
3. How long do results take and what does the report include?
The comprehensive report is delivered within 3 to 4 weeks, classifying every identified variant as pathogenic, likely pathogenic, or benign, and providing clear recommendations for family screening and clinical management.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is anonymized, encrypted, and stored on ISO 9001:2015 certified infrastructure. Clinical testing follows the guidelines of Federal Decree-Law No. 4 of 2016 on Medical Liability ensuring patient safety and informed consent.
Clinical & Logistical Metadata
| Test Name | SCN9A Gene Primary Erythromelalgia NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 – 4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or FTA card |
| Methodology Used | Next-Generation Sequencing (Illumina® platform) |
| ICD-10-CM Code | I73.81 (Erythromelalgia) |
| LOINC Code | 94026-8 (SCN9A gene full sequencing in blood) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians